The pharmaceutical sector is experiencing a important shift in glucose care with the arrival of GLP-1 transdermal devices. These revolutionary vehicles offer a potentially easy choice to subcutaneous injections for individuals dealing with type 2 diabetes. By circumventing the requirement for fre